-       Report 
   - June 2023
    -  150 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - July 2024
    -  172 Pages 
    Global
   
   From       €2243EUR$2,500USD£1,969GBP 
                -       Report 
   - April 2024
    -  181 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - July 2021
    -  50 Pages 
    China
   
   From       €2333EUR$2,600USD£2,048GBP 
                -       Report 
   - May 2024
    -  200 Pages 
    Global
   
   From       €3724EUR$4,150USD£3,268GBP 
                   -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - June 2024
    -  260 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                -       Report 
   - February 2024
    -  120 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  125 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  110 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - April 2023
    -  115 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  115 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                -       Report 
   - February 2024
    -  120 Pages 
    Global
   
   From       €4262EUR$4,750USD£3,741GBP 
                  -       Report 
   - May 2024
    -  128 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
                  -       Report 
   - May 2024
    -  140 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
                  -       Report 
   - May 2024
    -  128 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
                -       Report 
   - September 2025
    -  70 Pages 
    India
   
   From       €3141EUR$3,500USD£2,756GBP 
                -       Report 
   - April 2024
    -  185 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
             
         Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly    growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less   Read more